tetano
Editor, Senior Moderator
J Viral Hepat. 2012 Jan;19 Suppl 1:14-7. doi: 10.1111/j.1365-2893.2011.01521.x.
Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?
Sim?n-Talero M, Buti M, Esteban R.
Source
Liver Unit, Hospital Universitari Vall d'Hebron Department of Medicine, Universitat Aut?noma de Barcelona Centro de Investigaci?n Biom?dica en Red de Enfermedades Hep?ticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Barcelona, Spain.
Abstract
Summary. Treatment for hepatitis C virus is often complicated by anaemia from ribavirin-related haemolysis and bone marrow suppression because of peginterferon alfa. An extensive literature search revealed no reports of drug interactions between ribavirin and oseltamivir. We report the case of a patient with chronic hepatitis C infection who developed severe anaemia during antiviral treatment with peginterferon alfa/ribavirin when oseltamivir was added to treat influenza. The adverse events related to ribavirin and drug-drug interactions during therapy for hepatitis C are discussed.
? 2012 Blackwell Publishing Ltd.
PMID:
22233409
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/22233409
Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?
Sim?n-Talero M, Buti M, Esteban R.
Source
Liver Unit, Hospital Universitari Vall d'Hebron Department of Medicine, Universitat Aut?noma de Barcelona Centro de Investigaci?n Biom?dica en Red de Enfermedades Hep?ticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Barcelona, Spain.
Abstract
Summary. Treatment for hepatitis C virus is often complicated by anaemia from ribavirin-related haemolysis and bone marrow suppression because of peginterferon alfa. An extensive literature search revealed no reports of drug interactions between ribavirin and oseltamivir. We report the case of a patient with chronic hepatitis C infection who developed severe anaemia during antiviral treatment with peginterferon alfa/ribavirin when oseltamivir was added to treat influenza. The adverse events related to ribavirin and drug-drug interactions during therapy for hepatitis C are discussed.
? 2012 Blackwell Publishing Ltd.
PMID:
22233409
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/22233409